Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 6/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090349 | 0.79 | ALOX5 (0.41) | ALOX5KDM4ESLC6A4NPC1RAB9A | |
| SCHEMBL12064962 | 0.79 | CTSA (0.45) | ALOX5NPC1RAB9AFBP1CTSA | |
| SCHEMBL6011470 | 0.79 | FFAR2 (0.46) | ALOX5MAPTFBP1CTSA | |
| SCHEMBL5514812 | 0.79 | ALOX5 (0.41) | ALOX5KDM4ENPC1RAB9AFBP1 | |
| SCHEMBL6848050 | 0.79 | ALOX5 (0.52) | ALOX5KDM4ENPC1RAB9ACTSA | |
| SCHEMBL6182478 | 0.75 | SLC6A4 (0.50) | ALOX5KDM4ESLC6A4ACACB | |
| SCHEMBL4768669 | 0.75 | ALDH1A1 (0.42) | ALOX5KDM4EFBP1ADAM17CTSA | |
| SCHEMBL2523361 | 0.74 | CTSA (0.46) | ALOX5KDM4ENPC1POLBMAPT | |
| SCHEMBL31090348 | 0.73 | GAA (0.52) | KDM4ENPC1POLBMAPTRAB9A | |
| SCHEMBL29752075 | 0.72 | ACHE (0.52) | ALOX5RAB9ACTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100508978-C | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK & CO INC MERCK FROSST CA (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1363635-B1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| CN-1551769-A | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | — | 2004-12-01 | — | — | CN | disclosed |
| US-6740666-B2 | FOR THERAPY OF ASTHMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, EOSINOPHILIC GRANULOMA, PSORIASIS; SEPTIC SHOCK, ULCERATIVE COLITIS, CROHN'S DISEASE, REPERFUSION INJURY OF THE MYOCARDIUM AND BRAIN, INFLAMMATION | MERCK & CO., INC. | 2004-05-25 | — | — | US | disclosed |
| EP-1363635-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | Merck & Co., Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-10-03 | — | — | US | disclosed |
| EP-1244628-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002069970-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK & CO., INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-08-01 | — | — | US | disclosed |
| US-6410563-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIARTHRITIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-06-25 | — | — | US | disclosed |
| WO-2001046151-A1 | SUBSTITUTED 8-ARYLQUINOLINE PHOSPHODIESTERASE-4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103226-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE4C | ALOX5 2946/4885KDM4E 63/4885SLC6A4 308/4885 |
| US-20020143032-A1 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE12 | ALOX5 1269/4885KDM4E 367/4885SLC6A4 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.